卡巴胆碱对MODS病人肠功能障碍的治疗作用（英文）  

The Study on Carbachol Treatment of Gastrointestinal Dysfunction in Patients with MODS

作　　者：程爱斌[1] 张军伟[1] 谢宇曦[1] 余亮科[1] 高素玲[1] 罗永伟[1] 于志亮[1] 

机构地区：[1]河北联合大学附属医院重症医学科,河北唐山063000

出　　处：《药物生物技术》2015年第5期432-435,共4页Pharmaceutical Biotechnology

摘　　要：研究卡巴胆碱对MODS病人肠功能障碍的治疗作用。通过前瞻性、多中心、随机对照临床试验将入选病人随机分为两组,分别于入组0 h、用药后24,48,72 h、第7天或死亡前取血行血浆内毒素、血D-乳酸的测定。临床动态监测肠鸣音恢复情况、腹胀、排便、肠管积气、积液情况,以在上述各时点评定两组患者胃肠功能评分。卡巴胆碱治疗组与莫沙必利治疗组相比,血浆D-乳酸、内毒素及胃肠功能评分均有显著变化(P<0.05)。卡巴胆碱能有效改善MODS病人肠道功能、减轻其炎症反应。To study therapeutic value of carbachol on gastrointestinal dysfunction in patients with MODS, by a prospective, multi- center,randomized controlled clinical trials ,209 cases were selected randomly,who were divided into two groups of patients respectively. The groups of 0,24,48,72 h ,7 days after treatment or prior to death, the blood plasma endotoxin, plasma D-lactate determination were conducted. At the same time, assessing the score of two groups at each time point about gastrointestinal function and monitoring dynamically clinical recovery of bowel sounds, abdominal distension, defecation, intestinal pneumatosis, fluid situation were performed. Comparing with carbachol treatment group and mosapride treatment group, plasma D-lactate, endotoxin and gastrointestinal function scores changed significantly （ P 〈 0.05 ）. Carbachol can improve bowel function and reduce the inflammatory response of patients with MODS.

关 键 词：卡巴胆碱 莫沙必利 D-乳酸 内毒素 胃肠功能障碍 多脏器功能障碍综合症 

分 类 号：R57[医药卫生—消化系统]